Timeline

  • 2013

    OraSure announces new agreement with Thermo Fisher Scientific for Development and Distribution of Fully Automated Oral Fluid Drugs of Abuse Assays.
  • 2012

    OraSure receives FDA approval for the OraQuick® In-Home HIV Test – the first and only oral fluid rapid OTC HIV test approved in the U.S.
  • 2011

    OraSure acquires DNA Genotek, Inc., a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
  • 2011

    OraSure launches OraSure QuickFlu™ Rapid Flu A+B Test.
  • 2011

    OraQuick® HCV receives FDA approval for fingerstick whole blood and CLIA waiver.
  • 2010

    OraQuick HCV receives FDA approval with venous whole blood.
  • 2009

    OraQuick HCV receives the CE Mark.
  • 2007

    Receives CE Mark for OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test.
  • 2007

    Announces agreement with Schering-Plough to develop and promote rapid point-of-care oral Hepatitis C test.
  • 2006

    Signs Letter of Intent with Roche Diagnostics to Develop Fully Automated Oral Fluid Drugs of Abuse Assays.
  • 2004

    Receives Popular Science Magazine's "2004 Best of What's New" Award for OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test.
  • 2004

    Receives FDA approval for oral fluid use of OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test in June, and launches in October.
  • 2003

    Centers for Disease Control and Prevention launches its "Advancing HIV Prevention" initiative with OraQuick® as their cornerstone for its program. Compound W® FreezeOff™, the Company's cryosurgical wart removal product, is launched in the over-the-counter market.
  • 2002

    OraQuick® becomes the first rapid HIV-1 test approved in the U.S. by the FDA. OraSure completes construction of Tech III on the south side of Bethlehem. It is to become a world class manufacturing facility. Total size is 48,000 square feet.
  • 2000

    Leases 24,000 square feet in the John M. Cook Technology Center II. Merged with Epitope to form OraSure Technologies (NASDAQ: OSUR). Headquarters remain in Bethlehem. Company sold for $260 million and gives investors up to 70x ROI.
  • 1999

    Raises $9.2 million in venture capital. Sales grew 32% to $14 million. STC launches Intercept® Oral Fluid Drug Test service.
  • 1998

    Establishes international office in the Netherlands, sales grow 34% to $10.6 Million and acquired exclusive distribution rights for Epitope's OraSure® Oral Specimen Collection Device for use in drugs of abuse testing.
  • 1996

    Raises $4.6 Million in a private placement of common stocks, pre-money market capitalization at $2.5 million.
  • 1995

    Changes to STC Technologies, Inc. STC completes an asset purchase of Enzymatics and begins to sell the Q.E.D.® Saliva Alcohol Test. STC signs multiple part agreements to license UPT™ (Up-Converting Phosphor Technology) patents worldwide. Secures $3 Million in capital, interest free for three years to develop UPT™.
  • 1991

    SolarCare completes clinical trials, receives regulatory clearances and begins to set up distribution to sell the Histofreezer® Portable Cryosurgical System to physicians.
  • 1991

    SolarCare signs a license agreement with Coppertone to market SunSense® worldwide. SolarCare develops and sells a cotinine (nicotine metabolite) test to its first insurance customer.
  • 1987

    On December 11th, SolarCare Incorporated is founded and officially begins at the Ben Franklin Technology Center at Lehigh University, and shortly thereafter introduces SunSense®, a sunscreen on a towelette.